Targeting cancer cell death with a bcl-XS adenovirus.
Transformation is a complex cellular process that requires several genetic abnormalities. In many cases, one of these abnormalities is an inhibition of PCD, which provides a selective advantage for tumor cells. This has been recently shown in an in vivo model, where overexpression of Bcl-XL, is a crucial step in the progression from hyperplasia to neoplasia and is accompanied by a significant decrease in tumor apoptosis [56]. Frequently, overexpression of a member of the Bcl-2 family results in a block in cell death and appears to nullify many built-in cellular defense mechanisms against cancer. Such a block presents a problem because radiation and chemotherapy, standard cancer treatments, ultimately exert their effect by induction of apoptosis and would also be made less effective. Therefore, to better treat cancer it may be necessary to develop novel methods to overcome the effects of the Bcl-2 family. One way to approach this problem is to target the cause--the molecular machinery that allows a cancer cell to survive. Advances in our understanding of apoptosis has identified the Bcl-2 family as a mediator of most apoptosis pathways, including those initiated by oncogenes, tumor suppressor genes, growth factor withdrawal, and external damaging signals. Therefore, functional inhibition of Bcl-2 family members is lethal to many cancer cells. Using gene transfer technology, we can now deliver genes that accomplish this goal. Further investigation will reveal whether this translates to improved therapy in the future.
Han
J S
JS
Department of Internal Medicine, University of Michigan Medical School, Comprehensive Cancer Center, Ann Arbor 48109, USA.
Núñez
G
G
Wicha
M S
MS
Clarke
M F
MF
D000256:Adenoviridae / Q000235:genetics*; D017209:Apoptosis / Q000502:physiology; D016923:Cell Death / Q000235:genetics*; D016147:Genes, Tumor Suppressor; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D051020:bcl-X Protein
C494811:BCL2L1 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein